LOPROX (ciclopirox) by Eurofarma Laboratórios is protein synthesis inhibitors [moa]. First approved in 1988.
Drug data last refreshed 1h ago · AI intelligence enriched 1mo ago
LOPROX (ciclopirox) is a topical antifungal suspension approved in 1988 that inhibits fungal protein synthesis. It is used to treat superficial fungal infections of the skin, nails, and scalp. The drug works by disrupting protein synthesis in fungal cells, making it effective against a broad spectrum of dermatophytes and yeasts.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting smaller teams focused on cost management and market defense rather than growth initiatives.
Protein Synthesis Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP
Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers
Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer
Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis
Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children
Worked on LOPROX at Eurofarma Laboratórios? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LOPROX positions offer limited growth upside but valuable experience in mature product management, market defense, and generic competition strategy. Careers on this asset emphasize operational efficiency, cost management, and stakeholder retention rather than innovation or market expansion.